Organogenesis Holdings (ORGO) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Organogenesis Holdings

NasdaqCM•Healthcare•Drug Manufacturers - Specialty & Generic

$1.71+0.07(0.04%)Market closed

Market Cap

$175.00M

P/S

0.4x

P/B

1.2x

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.

How this company scores

AverageMetricSide Score: 53/100

Strongest: Cash & Earnings Quality (16/25); weakest: Profitability (7/25).

Profitability7/25

Growth15/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality16/25

Strengths

Interest easily coveredConsistent growthNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 107.6x5y range 7.0x – 537.8x

Currently above its 15-quarter median.

P/S · 0.4x5y range 0.4x – 4.2x

Currently below its 20-quarter median.

P/B · 1.2x5y range 1.0x – 10.0x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 4 quarters — monitor for earnings quality deterioration.

Price & Volume

Market Cap $175.00M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $457.45M
Q. Revenue: $43.76M
TTM EBITDA: $-19.93M
TTM Op. Income: $-35.87M
Q. Op. Income: $-50.99M
TTM Net Income: $-84.16M
Q. Net Income: $-96.27M
EPS: $-0.77
Shares Out.: $128.67M

$457.45M in TTM revenue grew 6.5% YoY, reaching $43.76M last quarter. TTM EBITDA of $-19.93M and TTM operating income of $-35.87M show growth is flowing through to the bottom line. However, net income is negative at $84.16M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 2 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 45.9%
EBITDA Margin: -108.2%
Op. Margin: -116.5%
Net Margin: -220.0%

Op. margin of -116.5% is down 104.1% YoY — costs are rising relative to revenue. Net margin at -220.0% and gross margin of 45.9% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 836% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 0.4x
P/B Ratio: 1.2x

P/S of 0.4x and P/B of 1.2x. P/S is low relative to typical market levels. Over the past year, P/E is up 0% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $406.45M
Cash: $46.10M
Long-Term Debt: N/A
Book Value: $148.27M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-31.65M
TTM Free Cash Flow: $20.84M
FCF Margin: 4.6%
FCF / Net Income: -0.2

TTM FCF of $20.84M on $-31.65M in operating cash flow. The FCF / Net Income ratio of -0.2x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has risen for 3 consecutive quarters — an improving trend.